ZIM Laboratories Ltd is planning to get listed on the National Stock Exchange on November 25th, 2022. ZIM Laboratories Limited, already listed on the BSE since June 2018, will now extend its listing to the NSE. As on date, has provided over 85% return to its investors from the listing price.
According to the September 2022 shareholding pattern available on BSE, the company’s promoters own 33.26% stake in the company of which, Dr Anwar Daud, Chairman and Managing Director owns 27.37% stake and Mathew Cyriac, Executive Chairman of Florintree
Advisors as an investor owns 21.86% stake.
The company has multiple innovative process technologies like Micro Emulsion Coating Technology (MECT) (Liquid In Pellets), Pellet Cold Forming Technology (PCFT), Rapid Gelation Drug Release Technology (RGDCT), Matrix Pore Forming Tablet Technology (MAPOTAB) etc., which it leverages to develop innovative generic pharmaceutical products including Oral Thin Films (OTF) using its patented Thinoral® technology. With a clear focus on growing its R&D capabilities, the company has been regularly investing in R&D and in H1FY23 has invested 7.3% of its total operating income into research initiatives.
Leveraging on its R&D strength, ZIM uses its proprietary technology platforms for developing, manufacturing and supplying of differentiated generic pharmaceutical and nutraceutical products in Finished Formulations (FF) as well as Pre-Formulation Intermediates (PFI) in various therapeutic categories which include Anti-Infective, Cardiovascular System, Gastrointestinal, Analgesic / NSAID, Urology, Vitamins and Dietary Supplements etc. The Company also provides comprehensive support for Product Conceptualisation, Product Development, Dossier Development, Marketing Authorisations, Manufacturing and Supply. Its business model is to partner with various pharmaceutical, marketing and distribution companies which seek solutions for development, sourcing and marketing of differentiated generic products.
Over the last 2 years (FY20 to FY22), Operating Income, EBITDA and PAT for the company has grown at a CAGR of 9.6%, 29% and 110% respectively. For the half year ending September 2022 (H1FY23), Operating Income grew 35.6% to Rs. 192crore against Rs. 141 crore for the same period last year (H1FY22). EBITDA for H1FY23 grew to Rs 26.8 crore Vs Rs 17.6 crore in H1 FY22 and Net Profit was at Rs. 10.6 crore in H1 FY23 Vs Rs 3.45 crore in H1FY22. Borrowings has also reduced from Rs 86.4 crore in H1 FY22 to Rs 63.3 crore in H1FY23. On November 12 th 2022, the Company also announced bonus issue of 2 shares for every 1 share held, subject to shareholder and other statutory approvals.